Myriad Genetics, Inc. will present multiple studies at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting the value of genetic insights to guide and clarify cancer treatment and risk assessment. The presentations underscore Myriad's commitment to partnering with oncologists and other healthcare partners to support health equity and provide data-driven insights to help guide clinical care and improve outcomes. They follow the recent launch of Precise™ Oncology Solutions, a comprehensive suite of solutions offering germline testing, tumor profiling, and companion diagnostic options, including evaluation for homologous recombination deficiency (HRD).

The suite offers a streamlined testing experience designed to help oncologists recommend personalized treatment plans for their patients.